Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a promising performance beauty company with a strong product portfolio in the medical aesthetic industry, specifically in the injectable neurotoxin and HA gel categories. The company has shown strength in its second quarter results and is confidently raising its revenue guidance. With the expected FDA approval of its flagship HA gel product, Sculpt, in 4Q26, Evolus is well-positioned to compete with other leading products in the market and drive account conversion. In addition, Evolus' focus on expanding its product offerings through strategic acquisitions and partnerships makes it an attractive target for both strategic and financial buyers. However, there are risks to consider, such as a challenging consumer spending environment, competition, and regulatory delays, which could impact the company's growth and financial performance. Overall, Evolus' strong product portfolio and strategic initiatives make it a compelling investment opportunity with potential for increased valuation in the future.

Bears say

Evolus is facing stiff competition from larger players in the medical aesthetics market, leading to potential struggles in capturing market share and maintaining profitability. Additionally, the company's reliance on one key product, Jeuveau, leaves it vulnerable to supply chain disruptions and potential loss of revenue if competitors introduce similar products. Furthermore, potential dilution through restructuring costs and litigation expenses could negatively impact the company's financials.

Evolus (EOLS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Evolus (EOLS) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.